Printer Friendly

Germany : Bayer to Present New Data on Advancing Oncology Portfolio.

Bayer HealthCare (Bayer) will present latest preclinical and clinical data on promising early-stage compounds with new mechanism of action at the American Association for Cancer Research (CR) 105th Annual Meeting, April 5-9, 2014, in San Diego, CA.

Bayer s presence at CR this year reflects both our progress and our commitment to advancing the research and development of innovative treatments for tumor types with a high medical need, said Dr. Karl Ziegelbauer, Head of Therapeutic Research Group Oncology/Gynecological Therapy at Bayer HealthCare. Cancer is a complex and heterogeneous disease. Being able to understand the molecular mechanisms driving different types of cancer will allow us to identify and develop novel targeted approaches to better treat this devastating disease.

Bayer will present new preclinical data, for example on three investigational agents currently in preclinical or Phase I clinical development targeting fibroblast growth factor receptors (FGFRs) whose increased expression is tied to tumor growth, angiogenesis, and chemoresistance. The agents include: a selective small molecule panFGFR1-3 kinase inhibitor (BAY 1163877); an anti-FGFR2 monoclonal antibody (BAY 1179470), as well as an FGFR2 antibody-drug conjugate (ADC). FGFR2-ADC carries a microtubule-disrupting agent, based on a technology licensed from Seattle Genetics, Inc. Through collaboration with the U.S.-based company, Bayer is also developing another ADC targeting tumors expressing C4.4a, a tumor-specific and metastases-associated tumor antigen. Preclinical evidence of anti-tumor efficacy of C4.4a-ADC as investigational agent for lung cancer patients will be presented.

Preventing the binding of bromodomain and extra-terminal (BET) family proteins to chromatin is a promising novel therapeutic approach in the fight against cancer. For the first time, Bayer will present data on a new class of benzodiazepine BET-inhibitors with improved oral bioavailability. Selective inhibition of positive transcription elongation factor b (P-TEFb) may add a new key mechanism of action to current cancer therapies via the suppression of anti-apoptotic signals. Bayer is working on a class of selective P-TEFb/CDK9-inhibitors, originally licensed from Lead Discovery Center GmbH and first preclinical data will be shown at CR.

Clinical Phase-I-results in patients with advanced stage small cell lung or ovarian cancer will be presented on the oral pan-CDK inihibitor Roniciclib (BAY 1000394). The anti-tumor agent, currently in Phase I/II testing, targets cyclin-dependent kinases (CDK) that are involved in crucial cellular functions such as tumor cell proliferation and survival signaling. New preclinical data are presented on two other Phase I investigational agents: BAY 1125976, a selective allosteric AKT1/2 inhibitor, and BAY 1082439.

2014 Al Bawaba ( Provided by , an company
COPYRIGHT 2014 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Apr 5, 2014
Previous Article:Germany,Spain,Switzerland : BARCELONA acquires ALEN HALILOVIC despite FIFA transfer ban.
Next Article:Germany,United Kingdom : FABRICOM OFFSHORE bags 4-year Maintenance contract for Nordsee Ost wind farm in GERMANY.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters